Oxford Cannabinoid Technologies Holdings Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCTP.L research report →
Companywww.oxcantech.com
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia.
- CEO
- Clarissa Ann Sowemimo-Coker
- IPO
- 2021
- Employees
- 7
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $1.25M
- P/E
- -0.19
- P/S
- 0.00
- P/B
- 0.28
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -86.76%
- ROIC
- -152.06%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-5,945,050 · -15.65%
- EPS
- $-0.01 · -14.81%
- Op Income
- $-7,037,609
- FCF YoY
- -27.83%
Performance & Tape
- 52W High
- $1.38
- 52W Low
- $0.12
- 50D MA
- $0.29
- 200D MA
- $0.59
- Beta
- 0.60
- Avg Volume
- 14.97M
Get TickerSpark's AI analysis on OCTP.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our OCTP.L Coverage
We haven't published any research on OCTP.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OCTP.L Report →